Novel Anti-lilrb4 antibodies and derivative products
Anti-LILRB4 antibodies and CARs address the challenge of targeting LILRB4 to treat refractory cancers by reducing tumor burden and enhancing immune activation, providing effective therapeutic options for AML and other malignancies.
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- IMMUNE ONC THERAPEUTICS INC
- Filing Date
- 2025-10-26
- Publication Date
- 2026-05-07
AI Technical Summary
There is a significant need for novel anti-LILRB4 antibodies to target LILRB4, a protein that inhibits immune cell activation and supports tumor cell infiltration, particularly in cancers such as acute myeloid leukemia (AML), which are refractory or relapsed, and current treatments are inadequate.
Development of anti-LILRB4 antibodies and antigen-binding fragments, including bispecific antibodies capable of binding to LILRB4 and CD3, with specific amino acid sequences, and their use in pharmaceutical compositions and chimeric antigen receptors (CAR) for targeted cancer therapy.
The antibodies and CARs effectively reduce tumor burden, inhibit tumor infiltration, and enhance immune cell activation, offering therapeutic options for various cancers, including drug-resistant forms of AML and other hematologic malignancies.
Smart Images
Figure US20260125467A1-D00000_ABST
Abstract
Citation Information
Cited By
Novel bispecific Anti-CD3 / CD20 polypeptide complex formulation
US20230279138A1